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Abstract
Mitochondrial DNA (mtDNA) is highly polymorphic at the population level, and specific mtDNA variants affect mitochondrial
function. With emerging evidence that mitochondrial mechanisms are central to common human diseases, it is plausible
that mtDNA variants contribute to the ‘‘missing heritability’’ of several complex traits. Given the central role of mtDNA genes
in oxidative phosphorylation, the same genetic variants would be expected to alter the risk of developing several different
disorders, but this has not been shown to date. Here we studied 38,638 individuals with 11 major diseases, and 17,483
healthy controls. Imputing missing variants from 7,729 complete mitochondrial genomes, we captured 40.41% of European
mtDNA variation. We show that mtDNA variants modifying the risk of developing one disease also modify the risk of
developing other diseases, thus providing independent replication of a disease association in different case and control
cohorts. High-risk alleles were more common than protective alleles, indicating that mtDNA is not at equilibrium in the
human population, and that recent mutations interact with nuclear loci to modify the risk of developing multiple common
diseases.
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Introduction
Mitochondria are the principal source of cellular adenosine
triphosphate (ATP) generated through oxidative phosphorylation
(OXPHOS), which is linked to the respiratory chain. In humans,
thirteen OXPHOS proteins are synthesised from the 16.5 Kb
mitochondrial genome (mtDNA). MtDNA has accumulated genetic
variants over time, and being strictly maternally inherited, under-
goes negligible intermolecular recombination. As a consequence,
ancient variants extant in the human population define haplogroups
that have remained geographically or ethnically restricted [1].Work
on European haplogroups has shown that some polymorphic
mtDNA variants affect mitochondrial function [2,3].
Given emerging evidence that mitochondria play a key role in
several common diseases, it is likely that variation of mtDNA could
alter the risk of developing different human disorders. Early
mtDNA genetic association studies were under-powered, and the
vast majority have not been replicated [4]. However, some recent
large studies have found replicable associations with specific
human diseases [5–11], most notably in sporadic Parkinson’s
disease [12–14]. These observations implicate mtDNA as part of
the ‘‘missing heritability’’ of complex human disease traits.
Ultimately, mtDNA codes for a limited number of proteins that
affect the same common pathway of energy production implicated
in several human diseases. It is likely, therefore, that functional
genetic variation of mtDNA will have impact on more than one
disease – but this has not been directly studied before. To test this
hypothesis, we analysed mtDNA SNP data from 51,106 subjects
from the Wellcome Trust Case Control Consortium, comparing
genotypes from 11 major diseases: ankylosing spondylitis (AS,
n = 2,005), ischemic stroke (IS, n = 4,205), multiple sclerosis (MS,
n = 11,377), Parkinson’s disease (PD, n= 2,197), primary biliary
cirrhosis (PBC, n= 1,921), psoriasis (PS, n= 2,622), schizophrenia
(SP, n= 2,019), ulcerative colitis (UC, n= 2,869), coronary artery
disease (CAD, n= 3,215), hypertension (HT, n= 2,943) and type-2
diabetes (T2D, n= 2,975) to three independent control groups
genotyped on the same platforms (WTCCC-58C, n= 2997,
WTCCC-NBS, n= 2897 andWTCCC2-MetabaloChip, n= 5841).
Results
Common mtDNA variants are associated with common
disease
After applying stringent quality control measures (Supple-
mentary Materials, Table S1 & S2), we initially compared the
two healthy control groups using PLINK v2.050 [15] (Supple-
mentary Materials, Figure S1), and found no significant
difference in allele frequencies. We therefore merged control
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groups genotyped on the same platform for all subsequent analyses
as follows: WTCCC-Control-1, WTCCC-Control-2 andWTCCC-
Control-3 (Supplementary Materials, Table S2).
Cluster plots produced by principle component analysis (PCA)
revealed no significant population stratification when comparing
either: datasets from the same array or array-specific control
datasets (Supplementary Materials, Figure S4).
We then compared genotyped SNPs in each disease group to
platform-matched control datasets using PLINK v2.050 [15]
(Figure 1 & Supplementary Materials, Table S3). This
confirmed previously reported associations at the low-resolution
haplogroup level [5,12,16,17], endorsing the methodological
approach.
Phylogenetically-related mtDNA variants are associated
with common disease
Next we performed lexical tree building to identify new
associations with phylogenetically related variants, but without
basing our anlysis on any prior assumptions related to the
published mtDNA haplogroup structure [18,19]. This method
uses fewer SNPs because individuals with missing SNP data cannot
be used, but has greated power, and provides graphical summaries
of the combinations of SNPs that are associated with increased or
descreased risk of disease (Supplementary Materials, Table
S4). Lexical tree analysis identified significant relationships
between the mtDNA tree structure and schizophrenia, primary
biliary cirrhosis, multiple sclerosis (each at p,1026), ulcerative
colitis (p,1024), and Parkinson’s disease (p = 0.004) (Table 1 and
Supplementary Materials Figure S3), independently con-
firming previous haplogroup based association associations
[5,12,16,17], and revealing new mtDNA clades associated with
several different diseases. The other case-control trees, and
comparisons between the different control populations were not
significant at the 1% level.
Imputed mtDNA variants are associated with several
different common diseases
To determine the functional basis of the associations we
imputed missing genotypes across the whole mitochondrial
genome using 7,729 complete mtDNA sequences. Subsequent
analyses were performed on 35,901 European cases and 15,302
European controls, and captured 40.41% of European mtDNA
population genetic variation (Supplementary Materials,
Figure S2).
In keeping with our original hypothesis, specific variants with
predicted functional consequences conferred either an increased
risk (Table 2a) or decreased risk (Table 2b) across several
different diseases. In addtion, we identified the same allelic-specific
associations for different diseases compared to different platform-
specific control groups, re-inforcing these findings. Functional
variants associated with an increased risk in two or more diseases
were limited to two structural genes: MTCYB (m.14793, m.15218)
and MTCO3 (m.9477, m.9667). The only non-synonmous protien
encoding variant consistently associated with a reduced risk of
disease was in MTND3 (m.10398).
We also found evidence of associations across multiple diseases
within the non-coding region (d-loop) of mtDNA, and 16S
ribosomal RNA subunit genes (Figure 2 and Table 2 and
Supplementary Materials, Table. S3). Intriguingly, the same
alleles were not associated with all of the diseases we studied, and
for two variants (m.11299, m.16294), the same allele had opposite
effects for two different diseases (Table 2c).
Overall, the majority of disease-associated alleles conferred an
increased risk (61/99), and not a decreased risk (38/99, P,0.001)
(Supplementary Materials, Table S3).
Discussion
Following stringent quality control, our initial analysis con-
firmed previous associations between mtDNA haplogroups and
common disease in a much larger data set. These findings were
independentely supported by lexical tree based analysis at higher
levels of statistical significance. Subsequent imputation of missing
genotypes captured .40% of European mtDNA population
genetic variation in 35,901 European cases and 15,302 European
controls. By simultaneously analysing eleven, ostensibly unrelated,
diseases we identified several imputed mtDNA variants that were
associated with more than one disease. The same associations were
seen in different disease groups compared to different control
groups. This provided confirmatory independent replication of a
disease association, and supports our original hypothesis that the
same genetic variants of mtDNA contribute to the risk of
developing several common complex diseases.
Variants increasing the risk of two or more diseases were limited
to MTCYB (m.14793, m.15218) and MTCO3 (m.9477, m.9667),
encoding variants in cytochrome b (H16R, T158A) and subunit 3
of cytochrome c oxidase (complex IV, V91L, N154S). Functional
variants of MTCYB have previosly been associated with several
human phenotypes [20–22], but the most compelling evidence of a
prior disease association is the increased risk of developing
blindness in subjects harboring the mtDNA mutations in MTND
genes known to cause Leber hereditary optic neuropathy (LHON),
where they synergistically interact with a primary LHON
mutation to cause a defect of OXPHOS complex I activity [23].
On the other hand, the only non-synonmous protien encoding
variant associated with a reduced risk of several diseases was
m.10398 in the MTND3 variant (complex I, T114A). m.10398
occurs twice on the human mtDNA phylogeny (homoplastic on
haplogroups J and K), and has previously been associated with a
reduced risk of Parkinson’s disease [14,24]. This variant has been
shown to reduce complex I activity, cytosolic calcium levels, and
the mitochondrial membrane potential [3,25,26] and thus may
reduce the level of reactive oxygen species, contributing to the
Author Summary
There is a growing body of evidence indicating that
mitochondrial dysfunction, a result of genetic variation in
the mitochondrial genome, is a critical component in the
aetiology of a number of complex traits. Here, we take
advantage of recent technical and methodological ad-
vances to examine the role of common mitochondrial DNA
variants in several complex diseases. By examining over
50,000 individuals, from 11 different diseases we show that
mitochondrial DNA variants can both increase or decrease
an individual’s risk of disease, replicating and expanding
upon several previously reported studies. Moreover, by
analysing several large disease groups in tandem, we are
able to show a commonality of association, with the same
mitochondrial DNA variants associated with several
distinct disease phenotypes. These shared genetic associ-
ations implicate a shared underlying functional effect,
likely changing cellular energy, which manifests as distinct
phenotypes. Our study confirms the important role that
mitochondrial DNA variation plays on complex traits and
additionally supports the utility of a GWAS-based ap-
proach for analysing mitochondrial genetics.
Mitochondrial DNA and Complex Disease
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underlying disease mechanim of several disorders.Variants in
MTCO3 are typically associated with primary mitochondrial
disorders [27,28], but have been also been indentified as risk
factors in Alzheimer’s disease [29,30], migrainous stroke [31] and
sporadic optic neuropathy [32]. M.9477 and m.9667 are non-
synonmous protien encoding variants which are cladally related;
present on haplogroup U sub branches (U5 and U5a1b,
respectively). Cybrid studies of haplogroup U show a reduction
in mtDNA copy number, resulting in a reduction in mitochondrial
protein synthesis and complex IV activity [3,25], impairing energy
production and likely contributing to disease.
We also noted disease associations with substitutions in the non-
coding region and ribosomal genes (Table 2 and Supplemen-
tary Materials, Table S3). Although highly polymorphic at the
population level (Figure 2), there is emerging evidence that both
regions can have functional effects either through an effect on
mtDNA replication, transcription or translation [33,34], as
proposed in Alzheimer’s disease [34].
It is intriguing that there were more functional variants
associated with an increased risk, than with a decreased risk of
disease (Table 2 and Supplementary Materials, Table S3).
This suggests that deleterious, novel sub-haplogroup variants have
not yet been removed from the population through natural
selection, possibly including the younger d-loop variants. This has
been observed in the nuclear genome in the rapidly expanding
human population [35,36], implying that the modern human
population is far from equilibrium. An alternative explantion is
that mtDNA alleles may escape purifying selection because the
Figure 1. Circularised Manhattan plots of imputed P values showing the association between mtDNA variants and eight complex
traits. Radial axis: –log(P-value) (where dark inner circle indicates P = 0.05 threshold). Circumference: position on the mitochondrial genome based on
the revised Cambridge Reference Sequence (rCRS, NC_012920) numbering in an anti-clockwise direction from 12 o’clock. Each gene is colour coded,
as shown on the figure.
doi:10.1371/journal.pgen.1004369.g001
Mitochondrial DNA and Complex Disease
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associated disease phenotype only becomes manifest after female
reproductive life.
For two variants (m.11299, m.16294), the same allele was
associated with an increased risk of developing one disease,
and a reduced risk of developing another (Table 2). Although
differences in the sample size post-QC provide one explana-
tion, these findings raise the possibility that different mtDNA-
mediated mechanisms are involved in different contexts,
perhaps because some variants have a greater impact on
bioenergetics, and others on the generation of reactive oxygen
species. Alternatively, it is conceivable that the relevance of
specific alleles may be context-specific, only excerting a
functional effect on a particular haplogroup background
[37]. Substantially larger whole mtDNA genome studies will
be required to detect clade-specific epistastic interactions if
they exist.
In some instances we observed multiple associations with
different variants found within the same phylogenetic cluster.
For example m.499 (K1a), m.11485 (K1a4) and m.11840
(K1a4a1) are known to reside within subdivisions of the major
haplogroup K, and all associated decreased risk of MS and IS.
Conversely, m.310 (U4a2) and m.3197 (U5) are distinct
subclades of the U associated with increased risk of PS, MS,
IS PD AS and UC. Although reassuring from a technical
perpective, this illustrates the challenge of mtDNA association
studies, where variants with a close ancestral relationship
inevitably co-segregate, making it difficult to determine which
alleles are responsible for the disease risk.
Finally, analysis of imputed data also revealed several different
mtDNA alleles asssociated with different diseases, often reaching
high levels of statistical significance (P,10210, Supplementary
Materials, Table S3). However, these findings should only be
considered preliminary and require independent replication in
other populations (where specific European haplogroup distribu-
tions can vary) and thus do not form the major focus of this report.
In conclusion, these findings underscore the role of mitochon-
drial mechanisms in the pathogenesis of common diseases, and
emphasise the importance of incorporating the mitochondrial
genome in comprehensive genetic association studies. Although
the strict phylogenetic stucture of maternally inherited mtDNA
makes it difficult to identify the precise variants responsible, higher
resolution genotyping at the whole mtDNA genome level will cast
further light on the genetic mechanisms, particularly if recurrent
homoplasies independently associate with phenotypes across
several clades.
Materials and Methods
This study used data generated through the Welcome Trust
Case Control Consortium. A full list of the corresponding
investigators who generated each dataset is available from
http://www.wtccc.org.uk/ccc2/wtccc2_studies.html [38–45].
Both case and control datasets were downloaded from the
European Genotype Archive (http://www.ebi.ac.uk/ega).
Psoriasis (PS), multiple sclerosis (MS), ischemic stroke (IS),
Parkinson’s disease (PD), primary biliary sclerosis (PBC) and
ankylosing spondylitis (AS) patient cohorts were genotyped using
the Illumina 610K quad array (Illumina San Diego California
USA) and were compared array specific controls, denoted here as
WTCCC-Control-1 (combined WTCCC-58C and WTCCC-
NBS) genotyped on the Illumina 1.2M Duo platform (Illumina
San Diego California USA). Illumina array systems contain 138
mtDNA variants.
Ulcerative colitis (UC), schizophrenia (SP) and their array-
specific controls, denoted here as WTCCC-Control-2 (combined,
WTCCC-58C and WTCCC-NBS), were genotyped using the
Table 1. Lexical tree analysis.
Disease Array Removed by QC
Rare haplotypes (,5 or
not in controls) removed Sample Size
Whole Tree
p-value
Ankylosing Spondylitis Illumina 610K 243 11 1751 0.30
Ischemic Stroke Illumina 610K 407 41 3757 0.015
Multiple Sclerosis Illumina 610K 1317 74 9985 ,1E-6
Parkinson’s Disease Illumina 610K 235 6 1956 0.19
Primary Biliary Cirrhosis Illumina 610K 145 11 1765 ,1E-6
Psoriasis Illumina 610K 285 7 2330 0.004
Control NBS Illumina 610K 127 4 2597 -
Control 58C Illumina 610K 171 7 2752 -
Type-2 Diabetes MetabaloChip 117 1 2857 0.085
Coronary Artery Disease MetabaloChip 46 0 3079 0.30
Hypertension MetabaloChip 87 0 2856 0.12
Control MetabaloChip 150 0 5691 -
Ulcerative Colitis Affymetrix SNP 6.0 172 7 2690 1.5E-5
Schizophrenia Affymetrix SNP 6.0 115 5 2950 ,1E-6
Control NBS Affymetrix SNP 6.0 149 12 2826 -
Control 58C Affymetrix SNP 6.0 190 11 2796 -
Quality control (QC), sample sizes and tests for association between disease and the tree. P values were estimated using 106 permutations of the tree labels.
doi:10.1371/journal.pgen.1004369.t001
Mitochondrial DNA and Complex Disease
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Affymetrix SNP6.0 array (Affymetrix, Santa Clara, CA). The
Affymetrix SNP6.0 array system contains 445 mtDNA variants.
Coronary artery disease (CAD), Type-2 diabetes (T2D) and
hypertension (HT) cohorts and their array specific controls,
denoted here as WTCCC-Control-3 (combined WTCCC-58C
and WTCCC-NBS), were genotyped using the MetabaloChip
array system [46]. The MetabaloChip array system contains 135
mtDNA variants.
To ensure valid comparisons, each disease sample set
wasonlycompared to its corresponding control array counter-
part(i.e. SNP6.0 cases were compared to SNP6.0 controls).’’
Statistical power
Given the case cohort sample sizes post QC (Supplementary
Materials, Table S1), the corresponding control cohorts (Supple-
mentary Materials, Table S1), an expected MAF of 0.01, an
a=3.8561023 to 3.9761024(averaging 13-126 tests dependent upon
specific dataset) and disease prevalences of: psoriasis = 2% [47],
multiple sclerosis = 1% [48], ischemic stroke = 1% [49], primary
biliary cirrhosis = 0.1% [50], Parkinson’s disease = 0.3% [51],
ankylosing spondylitis = 0.1% [52], ulcerative colitis = 0.1% [53],
schizophrenia = 0.33% [54], Type-2 diabetes = 10% [55], coro-
nary artery disease = 3% [56] and hypertension = 30% [57]; we
had .80% power to detect an effect size of .1.2 in each cohort
(specifically, psoriasis = 79.8%, multiple sclerosis = 93.2%, ische-
mic stroke = 84.5%, primary biliary cirrhosis = 79.9%, Parkinson’s
disease = 85.9%, ankylosing spondylitis = 85.4%, ulcerative coli-
tis = 78.9%, schizophrenia = 80.3%, Type-2 diabetes = 85.3%,
coronary artery disease = 82.6% and hypertension = 98.7%).
Power calculations were carried out using Genetic Power
Calculator [58].
Primary association analysis
Stringent quality control (QC) was applied to each individual
cohort (Table S1) [59]. Briefly, each cohort was pruned of
missing phenotypes (defined as -9 in the pedigree/sample files).
Poorly performing SNPs (genotyped= 0.1[59]), and subsequenctly,
samples were removed (individual missingness = 0.1 [59]) using
PLINK v2.050 [15]. Additionally non-European mtDNA
sequences (defined with m.8701A, m.8540T and 10873T) were
also removed [1,60,61]. Finally, to verify the quality of genotypes
cluster plots of normalized intensity for each SNP were generated
using R (http://www.R-project.org) and inspected.
In order to increase statistical power, WTCCC-58C and
WTCCC-NBS control cohorts were merged. Initially, we com-
pared the two healthy control groups (Supplementary Mate-
rials, Figure S1), and found no significant difference in allele
frequencies. Briefly, each control cohort was merged with its array
genotyped counterpart (Supplementary Materials, Table
S2). As with individual cohorts, MAF=0.00001, implemented in
PLINK v2.050 [15], was used to remove SNPs with missing
genotpyes (i.e. call = 0 0). Poorly performing SNPs (geno-
typed= 0.1[59]), and subsequenctly, samples were removed
(individual missingness = 0.1[59]) using PLINK v2.050 [15].
Finally, to correct for control popualtion stratitification, variant
frequency was compared between -58C and –NBS using ‘—assoc’
PLINK v2.050 (P threshold = 0.05) [15]. Variants with signifcantly
different 58C/NBS frequencies were removed. This QC lead to
Figure 2. High-resolution map of the non-coding region of mtDNA (d-loop) showing allele frequencies in 7,729 control subjects
and the position of alleles associated with eight common human diseases; where: AS=ankylosing spondylitis, IS = ischaemic
stroke, MS=multiple sclerosis, PD=Parkinson’s disease, PBC=primary biliary cirrhosis, UC=ulcerative colitis and SP= schizo-
phrenia. Alleles associated with multiple diseases are shown in Table 2. Alleles associated with single diseases are shown in Table S1. Y-axis: minor
allele frequency (MAF) in 7,729 control subjects. X-axis: position on the mitochondrial genome based on the revised Cambridge Reference Sequence
(rCRS, NC_012920) with corresponding regions annotated below.
doi:10.1371/journal.pgen.1004369.g002
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the formation of 3 merged control cohorts: WTCCC-Control-1,
WTCCC-Control-2 and WTCCC-Control-3.
Prior to association testing QC’d case cohorts were merged with
corresponding QC’d control cohorts (i.e. Multiple sclerosis versus
WTCCC-Control-1). Differential missingness tests, which statisti-
cally compare the frequency of ‘missing’ genotype data between
cases and controls were performed on each case-control compar-
ison [59]. Variants were removed when missingness was signifi-
cantly different (P =,1024) [59]. Allelic association was imple-
mented in PLINK v2.050 [15]. Given the discovery nature of the
experiment, statistical significance was defined as P,0.05.
Population stratification
Only ancestral Europeans, determined by mitchondrial
DNA genotype, were included in this study [1,60,61].
Additionally, population structure in each cohort (post-QC)
and combined by array type was assessed by principle
component analysis (PCA) of mitochondrial DNA variants
[62]. Plots were made of the first two components for each
array dataset (Illumina = AS, IS, MS, NBS, PBC, PD, PS,
WTCCC-58C and WTCCC-NBS, Affymetrix = SP, UC,
WTCCC-58C and WTCCC-NBS and Metabalo = T2D,
CAD, HT and controls [previously combined WTCCC-58C
and WTCCC-NBS]) and separately for the control cohorts for
each platform (Supplementary Figure S3). At this resolution,
individual PCA cluster analysis showed no significant stratifi-
cation differences. All principle component scores were
calculated in R using the ‘princomp’ function and plotted in
R using ggplot (R Core Team 2013) [63].
Imputation
Imputation was implemented in PLINK v2.050 [15]. Initially a
reference panel was constructed. Whole Human mtDNA genome
data, n= 18,114 sequences, were downloaded from the National
Centre for Biotechnology Information Nucleotide database
(http://www.ncbi.nlm.nih.gov/nuccore/), using the keyword
phrase ‘Homo [Organism] AND gene_in_mitochondrion[PROP]
AND 14000:19000[SLEN] NOT pseudogene[All Fields]’. Se-
quences with pathogenic mtDNA variants (available at www.
mitomap.org) were removed (n = 458 sequences), non Homo sapien
sequences were removed (n = 7). Similar to genotype QC, non-
European mtDNA sequences (defined with m.8701A, m.8540T
and 10873T) were also removed (n= 7051). Finally truncated
mtDNA sequences (,16,500 bp) were removed (n = 663) leaving a
final dataset of n= 9,935 sequences. The sequence dataset was
aligned using MUSCLE [64], analysed using Haplogrep [65,66]
and subsequently filtered to match the Major European
haplogroups (H, V, J, T, U, K, W, X, I, R and N) leaving a
final sequence aplosamples and 2,873 variants, representing 100%
of of the genetic varation in the reference dataset.
The reference panel was merged with each QC’d case-control
cohort in PLINK (v2.050),[15] invoking ‘—flip-scan’ to detect and
correct any stranding issues. Imputation association testing was
carried out using ‘—proxy-assoc’ and, in order to assess the
imputation performance, ‘—proxy-drop’.[15] Significant SNPs
associations with .99% of samples imputed, number of proxy
SNPS .3, a MAF .0.01 and a content metric .0.8 were
retained.[15] Given a popualtion size of 7,729 and total genotypic
information of 2,873 as 100%, imputation of alleles with MAF.
0.0 captures 40% of total mtDNA genetic variabilty (Figure S2).
Circularised Manhattan plot
Cicularised Manhattan plots were generated using code
adapted from http://gettinggeneticsdone.blogspot.co.uk/2013/
11/a-mitochondrial-manhattan-plot.html, solarplot.R and ggplot2
(http://ggplot2.org/).
Lexical tree analysis
Lexical tree analysis was performed in R (R Core Team 2013)
[63] using a custom library (snptree, publically available from
http://www.staff.ncl.ac.uk/i.j.wilson/). This analysis was per-
formed on the Illumina 610K quad array, the Affymetrix
SNP6.0 and the MetabaloChip datasets independently. An
independent stringent QC was performed, removing in order:
the SNPs with a call rate of below 95% or a MAF of below
0.5%, the 2% of individuals with the most missing sites, the
bottom 50% of SNPs with the most missing samples at that site,
and those individuals with any missing data from the remaining
SNPs. Finally, those individuals with haplotypes (defined by all
the remaining SNPs) that were not present in controls or had a
frequency of less than 5 were removed. This left 27054
individuals on 24 SNPs for the Illumina 610K quad array,
10,745 individual at 15 SNPs for the Affymetrix 6.0 chip and
14,484 individuals at 5 SNPs for the MetabaloChip. The SNPs
retained and their minor allele frequencies (MAF) in the control
populations are shown in Supplementary Materials, Table
S4. A tree structure was contructed for haplotypes made from
the retained SNPs by initially grouping all individuals at the root
of a tree, and then successively considering all retained SNPs in
decreasing order of their minor allele frequency (Supplemen-
tary Materials, Figure S3). At each stage, the haplotypes at
each leaf node are split with those with the wild type being put
on the left branch and those with the mutant allele on the right.
This creates a tree with all leaves representing complete
haplotypes and internal nodes partial haplotypes. Test statistics
were then calculated for each node on the tree. An overall test
statistic for the tree was calculated by calculating the the sum of
the five largest node values that were not ancestors or
descendents of each other. The test statistic was tested for
significance by 1,000,000 random permutations of the Case/
Control labels.
Supporting Information
Figure S1 Mitochondrial DNA control allele frequencies after
quality control (see methods). Comparison of the WTCCC-58C
and WTCCC-NBS control cohorts. Solid line = linear regression
for the Illumina data. Dotted line = linear regression for the
Affymetrix data. MAF=minor allele frequency.
(DOCX)
Figure S2 Frequency distribution histogram showing the
percentage frequency of mitochondrial DNA variants in the
imputation reference panel (2,873 variants from 7,729 subjects)
plotted against the minor allele frequency (MAF) in the reference
panel. 40.41% variants have a MAF.0.01. These variants were
included in the imputation analysis.
(DOCX)
Figure S3 Lexical tree analysis of complex trait SNP data.
Shown are skeletal tree configurations for each genotyping
platform, control data comparisons (WTCCC-58C versus
WTCCC-NBS for each platform, showing no significant
haplotype associations) and case-control comparisons on each
skeletal tree. Numbers indicate nodal frequencies and significant
associations are highlighted in colour, where blue boxes indicate
a protective haplotype association. AS =Ankylosing spondylitis,
IS = ischaemic stroke, MS=multiple sclerosis, PD= Parkinson’s
disease, PBC= primary biliary cirrhosis, PS = psoriasis,
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SP = schizophrenia, UC= ulcerative colitis, CAD= coronary
artery disease, HT= hypertension, and T2D= type 2 diabetes.
(DOCX)
Figure S4 – PCA analysis of mtDNA variants, showing
clustering of: a) combined Illumina array cohorts (AS, IS, MS,
NBS, PBC, PD, PS, WTCCC-58C and WTCCC-NBS); b)
Illumina genotype controls only (WTCCC-58C and WTCCC-
NBS); c) combined Affymetrix array cohorts (SP, UC, WTCCC-
58C and WTCCC-NBS); d) Affymetrix genotype controls only
(WTCCC-58C and WTCCC-NBS) and e) combined Metabalo
array cohorts (T2D, CAD, HT and controls [previously combined
WTCCC-58C and WTCCC-NBS]).
(DOCX)
Table S1 Impact of quality control procedure on the number of
samples and genotypes (see methods). MAF=minor allele
frequency.
(DOCX)
Table S2 Impact of quality control procedure when combining
control data (see methods).
(DOCX)
Table S3 Association between imputed mitochondrial DNA
variants and eight complex diseases, showing the corresponding
control cohort, array SNP ID, variant position in the mitochon-
drial genome (rCRS, NC_012920), minor allele frequency in cases
and controls (A1-cases and A1-Cont. respectively), case-control
comparison (chi-square test P, na=not available in primary
analysis), imputed significance (P) and odds ratio (OR). Hap= -
corresponding major and sub mitochondrial haplogroup.
(DOCX)
Table S4 Mitochondrial DNA variants used to the lexical tree
analysis (see methods). Variant position in the mitochondrial
genome is based on the revised Cambridge reference sequence
(rCRS, NC_012920).
(DOCX)
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